Rapid Medical™, a leading developer of advanced neurovascular devices, announced Chinese approval of its TIGERTRIEVER revascularization device. With this milestone approval from the National Medical Products Administration (NMPA), TIGERTRIEVER becomes the first device to offer patient-specific solutions to remove blood clots from the brain to advance the treatment of stroke ischemic brains.
“This new approval for TIGERTRIEVER propels the treatment of ischemic stroke patients in China,” said Ronen Eckhouse , co-founder and CEO of Rapid Medical. “We are fortunate to have a great partner, MicroPort Scientific Corporation , who understands the need to expand neuro-interventional capabilities and individualized stroke care for these patients. »
TIGERTRIEVER technology, the result of advances in aerospace engineering, allows precise control during mechanical thrombectomy. Its exceptional functionality moves these procedures from a passive to an active approach that accelerates clot capture and potentially reduces the risk of vascular injury during extraction. The main comparable stent retrievers are self-expanding and static, which can lead to suboptimal clot removal and minimal vessel protection.
Published clinical studies show superiority over conventional stent retrievers. Results from the multicenter TIGER trial showed three statistically significant improvements – restoration of blood flow to the brain, good clinical outcomes and reduction of emboli to new territories – compared to the average of six pivotal stent retriever trials. 1 In addition, the TIGER trial demonstrated fast procedure times comparable to aspiration alone 2 , thanks to a very high first-pass success rate.
“The successful launch of TIGERTRIEVER in China represents another innovation in stroke intervention that can be applied in the real world, introducing the concept of tailored thrombectomy using an adjustable stent retriever that allows patients to physicians to navigate procedures and unexpected circumstances with increased control,” said Zhiyong Xie, president at MicroPort NeuroTech . “TIGERTRIEVER offers Chinese doctors a new choice of neurological intervention medical devices that will benefit more patients”.
Source link: https://www.businesswire.com/
